Molecular mechanisms of anthracyclines action;Molekularne mechanizmy działania antracyklin

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 60, Issue , 2006, Pages 78-100

  Szuławska, Agata ^a   Czyz, Małgorzata ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Anthracyclines; Apoptosis; Differentiation; Free radicals; Interaction with DNA; Intercalation; Topoisomerase II; Virtual crosslinks

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); REACTIVE OXYGEN METABOLITE;

ANIMAL; BIOSYNTHESIS; CELL PROLIFERATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; REVIEW;

ANIMALS; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DNA; DNA TOPOISOMERASES, TYPE II; DRUG DELIVERY SYSTEMS; ENGLISH ABSTRACT; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; REACTIVE OXYGEN SPECIES;

EID: 33846093647     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: None     Document Type: Review

References (167)

1. Addadi-Rebbah S., Poitevin S., Fourre N., Polette M., Garnotel R., Jeannesson P.: Assessment of the antiinvasive potential of anthracycline aclacinomycin (Aclarubicin) in human fibrosarcoma cell line. Int. J. Oncol., 2004; 24: 1607-1615
2. Arai M., Tomaru K., Takizawa T., Sekiguchi K., Yokoyama T., Suzuki T., Nagai R.: Sarcoplasmic reticulum genes are selectively down-regulated in cardiomyopathy produced by doxorubicin in rabbits. J. Mol. Cell Cardiol., 1998; 30: 243-254
3. Arcamone F., Animati F., Bigioni M., Capranico G., Caserini C., Cipollone A., De Cesare M., Ettorre A., Guano F., Manzini S., Monteagudo E., Pratesi G., Salvatore C., Supino R., Zunino F.: Configurational requirements of the sugar moiety for the pharmacological activity of anthracycline disaccharides. Biochem. Pharmacol., 1999; 57: 1133-1139
4. Ashikawa K., Shishodia S., Fokt I., Priebe W., Aggarwal B.B.: Evidence that activation of nuclear factor-kappaB is essential for the cytotoxic effects of doxorubicin and its analogues. Biochem. Pharmacol., 2004; 67: 353-364
5. Bachur N.R., Lun L., Sun P.M., Trubey C.M., Elliott E.E., Egorin M.J., Malkas L., Hickey R.: Anthracycline antibiotic blockade of SV40 T antigen helicase action. Biochem. Pharmacol., 1998; 55: 1025-1034
6. Bachur N.R., Yu F., Johnson R., Hickey R., Wu Y., Malkas L.: Helicase inhibition by anthracycline anticancer agents. Mol. Pharmacol., 1992; 41: 993-998
7. Bailly C., Suh D., Waring M.J., Chaires J.B.: Binding of daunomycin to diaminopurine-and/or inosine-substituted DNA. Biochemistry, 1998; 37: 1033-1045
8. Batist G., Ramakrishnan G., Rao C.S., Chandrasekharan A., Gutheil J., Guthrie T., Shah P., Khojasteh A., Nair M.K., Hoelzer K., Tkaczuk K., Park Y.C., Lee LW.: Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J. Clin. Oncol., 2001; 19: 1444-1454
9. Bertheau P., Plassa F., Espie M., Turpin E., de Roquancourt A., Marty M., Lerebours F., Beuzard Y., Janin A., de The H.: Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet, 2002; 360: 852-854
10. Binaschi M., Bigioni M., Cipollone A., Rossi C., Goso C., Maggi C.A., Capranico G., Animati F.: Anthracyclines: selected new developments. Curr. Med. Chem. Anticancer Agents, 2001; 1: 113-130
11. Binaschi M., Capranico G., Dal Bo L., Zunino F.: Relationship between lethal effects and topoisomerase II-mediated double-stranded DNA breaks produced by anthracyclines with different sequence specificity. Mol. Pharmacol., 1997; 51: 1053-1059
12. Binaschi M., Farinosi R., Borgnetto M.E., Capranico G.: In vivo site specificity and human isoenzyme selectivity of two topoisomerase IIpoisoning anthracyclines. Cancer Res., 2000; 60: 3770-3776
13. Bloch A.: Dynamics of interaction between DNA-specific antitumor agents and serum-contained cytokines in the initiation of ML-1 human myeloblastic leukemia cell differentiation. Leukemia, 1993; 7: 1219-1224
14. Borchmann P., Hubel K., Schnell R., Engert A.: Idarubicin: A brief overview on pharmacology and clinical use. Int. J. Clin. Pharmacol. Ther., 1997; 35: 80-83
15. Brana M.F., Cacho M., Gradillas A., de Pascual-Teresa B., Ramos A.: Intercalators as anticancer drugs. Curr. Pharm. Des., 2001; 7: 1745-1780
16. Burke B.E., Olson R.D., Cusack B.J., Gambliel H.A., Dillmann W.H.: Anthracycline cardiotoxicity in transgenic mice overexpressing SR Ca2+-ATPase. Biochem. Biophys. Res. Commun., 2003; 303: 504-507
17. Chaires J.B.: Energetics of drug-DNA interactions. Biopolymers, 1997; 44: 201-215
18. Chaires J.B., Fox K.R., Herrera J.E., Britt M., Waring M.J.: Site and sequence specificity of the daunomycin-DNA interaction. Biochemistry, 1987; 26: 8227-8236
19. Chaires J.B., Herrera J.E., Waring M.J.: Preferential binding of daunomycin to 5'ATCG and 5'ATGC sequences revealed by footprinting titration experiments. Biochemistry, 1990; 29: 6145-6153
20. Chaires J.B., Satyanarayana S., Suh D., Fokt I., Przewloka T., Priebe W.: Parsing the free energy of anthracycline antibiotic binding to DNA. Biochemistry, 1996; 35: 2047-2053
21. Chenais B., Andriollo M., Guiraud P., Belhoussine R., Jeannesson P.: Oxidative stress involvement in chemically induced differentiation of K562 cells. Free Radic. Biol. Med., 2000; 28: 18-27
22. Clementi M.E., Giardina B., Di Stasio E., Mordente A., Misiti F.: Doxorubicin-derived metabolites induce release of cytochrome C and inhibition of respiration on cardiac isolated mitochondria. Anticancer Res., 2003; 23: 2445-2450
23. Cullinane C., Cutts S.M., van Rosmalen A., Phillips D.R.: Formation of adriamycin-DNA adducts in vitro. Nucleic Acids Res., 1994; 22: 2296-2303
24. Cullinane C., Phillips D.R.: Induction of stable transcriptional blockage sites by adriamycin: GpC specificity of apparent adriamycin-DNA adducts and dependence on iron(III) ions. Biochemistry, 1990; 29: 5638-5646
25. Cullinane C., Phillips D.R.: Thermal stability of DNA adducts induced by cyanomorpholinoadriamycin in vitro. Nucleic Acids Res., 1993; 21: 1857-1862
26. Cutts S.M., Swift L.P., Rephaeli A., Nudelman A., Phillips D.R.: Sequence specificity of adriamycin-DNA adducts in human tumor cells. Mol. Cancer Ther., 2003; 2: 661-670
27. Czyz M., Szuławska A.: Indukowane róznicowanie komórek białaczkowych linii K562. Post. Hig. Med. Dos̈w., 2005; 59: 82-97
28. Czyz M., Szulawska A., Bednarek A.K., Duchler M.: Effects of anthracycline derivatives on human leukemia K562 cell growth and differentiation. Biochem. Pharmacol., 2005; 70: 1431-1442
29. DeFeo-Jones D., Garsky V.M., Wong B.K., Feng D.M., Bolyar T., Haskell K., Kiefer D.M., Leander K., McAvoy E., Lumma P., Wai J., Senderak E.T., Motzel S.L., Keenan K., Van Zwieten M., Lin J.H., Freidinger R., Huff J., Oliff A., Jones R.E.: A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo. Nat. Med., 2000; 6: 1248-1252
30. de Groot F.M., Broxterman H.J., Adams H.P., van Vliet A., Tesser G.I., Elderkamp Y.W., Schraa A.J., Kok R.J., Molema G., Pinedo H.M., Scheeren H.W.: Design, synthesis, and biological evaluation of a dual tumor-specific motive containing integrin-targeted plasmin-cleavable doxorubicin prodrug. Mol. Cancer Ther., 2002; 1: 901-911
31. Dimri G.P., Nakanishi M., Desprez P.Y., Smith J.R., Campisi J.: Inhibition of E2F activity by the cyclin-dependent protein kinase inhibitor p21 in cells expressing or lacking a functional retinoblastoma protein. Mol. Cell Biol., 1996; 16: 2987-2997
32. Doroshow J.H., Synold T.W., Somlo G., Akman S.A., Gajewski E.: Oxidative DNA base modifications in peripheral blood mononuclear cells of patients treated with high-dose infusional doxorubicin. Blood, 2001; 97: 2839-2845
33. Drummond D.C., Meyer O., Hong K., Kirpotin D.B., Papahadjopoulos D.: Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev., 1999; 51: 691-743
34. Dubois V., Dasnois L., Lebtahi K., Collot F., Heylen N., Havaux N., Fernandez A.M., Lobl T.J., Oliyai C., Nieder M., Shochat D., Yarranton G.T., Trouet A.: CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity. Cancer Res., 2002; 62: 2327-2331
35. Escobar P.F., Markman M., Zanotti K., Webster K., Belinson J.: Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer. J. Cancer Res. Clin. Oncol., 2003; 129: 651-654
36. Ettorre A., Cirilli M., Ughetto G.: Degradation of the morpholino ring in the crystal structure of cyanomorpholinodoxorubicin complexed with d(CGATCG). Eur. J. Biochem., 1998; 258: 350-354
37. Farnham P.J., Slansky J.E., Kollmar R.: The role of E2F in the mammalian cell cycle. Biochim. Biophys. Acta, 1993; 1155: 125-131
38. Fassas A., Anagnostopoulos A.: The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia. Leuk. Lymphoma, 2005; 46: 795-802
39. Fenick D.J., Taatjes D.J., Koch T.H.: Doxoform and Daunoform: anthracycline-formaldehyde conjugates toxic to resistant tumor cells. J. Med. Chem., 1997; 40: 2452-2461
40. Fornari F.A. Jr, Jarvis D.W., Grant S., Orr M.S., Randolph J.K., White F.K., Gewirtz D.A.: Growth arrest and non-apoptotic cell death associated with the suppression of c-myc expression in MCF-7 breast tumor cells following acute exposure to doxorubicin. Biochem. Pharmacol., 1996; 51: 931-940
41. Fornari F.A., Randolph J.K., Yalowich J.C., Ritke M.K., Gewirtz D.A.: Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol. Pharmacol., 1994; 45: 649-656
42. Frederick C.A., Williams L.D., Ughetto G., van der Marel G.A., van Boom J.H., Rich A., Wang A.H.: Structural comparison of anticancer drug-DNA complexes: adriamycin and daunomycin. Biochemistry, 1990; 29: 2538-2549
43. Gabizon A., Shmeeda H., Barenholz Y.: Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin. Pharmacokinet., 2003; 42: 419-436
44. Gale E.F., Cundliffe E., Reynolds P.E., Richmond M.H., Waring M.J.: The molecular basis of antibiotic action. Wiley, New York 1981, 258-401
45. Gamba-Vitalo C., Blair O.C., Tritton T.R., Lane P.A., Carbone R., Sartorelli A.C.: Cytotoxicity and differentiating actions of adriamycin in WEHI-3B D+ leukemia cells. Leukemia, 1987; 1: 188-197
46. Gao Y.G., Priebe W., Wang A.H.: Substitutions at C2' of daunosamine in the anticancer drug daunorubicin alter its DNA-binding sequence specificity. Eur. J. Biochem., 1996; 240: 331-335
47. Gariboldi M.B., Ravizza R., Riganti L., Meschini S., Calcabrini A., Marra M., Arancia G., Dolfini E., Monti E.: Molecular determinants of intrinsic resistance to doxorubicin in human cancer cell lines. Int. J. Oncol., 2003; 22: 1057-1064
48. Geroni C., Ripamonti M., Arrigoni C., Fiorentini F., Capolongo L., Moneta D., Marchini S., Della Torre P., Albanese C., Lamparelli M.G., Ciomei M., Rossi R., Caruso M.: Pharmacological and toxicological aspects of 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): A novel antineoplastic agent. Cancer Res., 2001; 61: 1983-1990
49. Gewirtz D.A.: A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol., 1999; 57: 727-741
50. Gill P.S., Espina B.M., Muggia F., Cabriales S., Tulpule A., Esplin J.A., Liebman H.A., Forssen E., Ross M.E., Levine A.M.: Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J. Clin. Oncol., 1995; 13: 996-1003
51. Gille L., Nohl H.: Analyses of the molecular mechanism of adriamycininduced cardiotoxicity. Free Radic. Biol. Med., 1997; 23: 775-782
52. Gillet R., Bobichon H., Trentesaux C.: Nuclear transcription factor GATA-1 is activated during aclacynomycin-induced erythroid differentiation. Biol. Cell, 2002; 94: 267-273
53. Gniazdowski M., Cera C.: The effects of DNA covalent adducts on in vitro transcription. Chem. Rev., 1996; 96: 619-634
54. Gniazdowski M., Denny W.A., Nelson S.M., Czyz M.: Transcription factors as targets for DNA-interacting drugs. Curr. Med. Chem., 2003; 10: 909-924
55. Gniazdowski M., Szmigiero L.: Molekularne mechanizmy oddziaływania związków przeciwnowotworowych na DNA. Na Pograniczu Chemii i Biologii, 2003; 7: 45-73
56. Grant D.S., Williams T.L., Zahaczewsky M., Dicker A.P.: Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int. J. Cancer, 2003; 104: 121-129
57. Green P.S., Leeuwenburgh C.: Mitochondrial dysfunction is an early indicator of doxorubicin-induced apoptosis. Biochim. Biophys. Acta, 2002; 1588: 94-101
58. Guano F., Pourquier P., Tinelli S., Binaschi M., Bigioni M., Animati F., Manzini S., Zunino F., Kohlhagen G., Pommier Y., Capranico G.: Topoisomerase poisoning activity of novel disaccharide anthracyclines. Mol. Pharmacol., 1999; 56: 77-84
59. Halford S., Yip D., Karapetis C.S., Strickland A.H., Steger A., Khawaja H.T., Harper P.G.: A phase II study evaluating the tolerability and effi-cacy of CAELYX (liposomal doxorubicin, Doxil) in the treatment of unresectable pancreatic carcinoma. Ann. Oncol., 2001; 12: 1399-1402
60. Harris L., Batist G., Belt R., Rovira D., Navari R., Azarnia N., Welles L., Winer E.: TLC D-99 Study Group. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer, 2002; 94: 25-36
61. Harrison P.M., Arosio P.: The ferritins: molecular properties, iron storage function and cellular regulation. Biochim. Biophys. Acta, 1996; 1275: 161-203
62. Iliskovic N., Singal P.K.: Lipid lowering: an important factor in preventing adriamycin-induced heart failure. Am. J. Pathol., 1997; 150: 727-734
63. Jeannesson P., Lahlil R., Chenais B., Devy L., Gillet R., Aries A., Morceau F., Trentesaux C.: Anthracycline as tumor cell differentiating agents: effects on the regulation of erythroid gene expression. Leuk. Lymphoma, 1997; 26: 575-587
64. Jeannesson P., Trentesaux C., Gerard B., Jardillier J.C., Ross K.L., Tokes Z.A.: Induction of erythroid differentiation in human leukemic K562 cells by membrane-directed action of adriamycin covalently bound to microspheres. Cancer Res., 1990; 50: 1231-1236
65. Jeyaseelan R., Poizat C., Baker R.K., Abdishoo S., Isterabadi L.B., Lyons G.E., Kedes L.: A novel cardiac-restricted target for doxorubicin. CARP, a nuclear modulator of gene expression in cardiac progenitor cells and cardiomyocytes. J. Biol. Chem., 1997; 272: 22800-22808
66. Johnston S.R., Gore M.E.: Caelyx: phase II studies in ovarian cancer. Eur. J. Cancer, 2001; 37(Suppl.9): S8-S14
67. Kang Y J., Zhou Z.X., Wang G.W., Buridi A., Klein J.B.: Suppression by metallothionein of doxorubicin-induced cardiomyocyte apoptosis through inhibition of p38 mitogen-activated protein kinases. J. Biol. Chem., 2000; 275: 13690-13698
68. Kastan M.B., Onyekwere O., Sidransky D., Vogelstein B., Craig R.W.: Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 1991; 51: 6304-6311
69. Kelman Z.: PCNA: structure, functions and interactions. Oncogene, 1997; 14; 629-640
70. Kim Y., Ma A.G., Kitta K., Fitch S.N., Ikeda T., Ihara Y., Simon A.R., Evans T., Suzuki Y.J.: Anthracycline-induced suppression of GATA-4 transcription factor: implication in the regulation of cardiac myocyte apoptosis. Mol. Pharmacol., 2003; 63: 368-377
71. Koukourakis M.I., Koukouraki S., Fezoulidis I., Kelekis N., Kyrias G., Archimandritis S., Karkavitsas N.: High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours. Br. J. Cancer, 2000; 83: 1281-1286
72. Kwok J.C., Richardson D.R.: Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: inhibition of the ferritin iron mobilization pathway. Mol. Pharmacol., 2003; 63: 849-861
73. Kwok J.C., Richardson D.R.: Examination of the mechanism(s) involved in doxorubicin-mediated iron accumulation in ferritin: studies using metabolic inhibitors, protein synthesis inhibitors, and lysosomotropic agents. Mol. Pharmacol., 2004; 65: 181-195
74. Langlois d' Estaintot B., Gallois B., Brown T., Hunter W.N.: The molecular structure of a 4'-epiadriamycin complex with d(TGATCA) at 1.7A resolution: comparison with the structure of 4'-epiadriamycin d(TGTACA) and d(CGATCG) complexes. Nucleic Acids Res., 1992; 20: 3561-3566
75. Laurent G., Jaffrezou J.P.: Signaling pathways activated by daunorubicin. Blood, 2001; 98: 913-924
76. Leng F., Priebe W., Chaires J.B.: Ultratight DNA binding of a new bisintercalating anthracycline antibiotic. Biochemistry, 1998; 37: 1743-1753
77. Leng F., Savkur R., Fokt I., Przewloka T., Priebe W., Chaires J.B.: Base Specific and Regioselective Chemical cross-linking of daunorubicin to DNA. J. American Chem. Soci., 1996; 118: 4731-4739
78. Licata S., Saponiero A., Mordente A., Minotti G.: Doxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reduction. Chem. Res.Toxicol., 2000; 13: 414-420
79. Lothstein L., Israel M., Sweatman T.W.: Anthracycline drug targeting: cytoplasmic versus nuclear-A fork in the road. Drug Resist. Updat., 2001; 4: 169-177
80. Lozzio C.B., Lozzio B.B.: Human chronic myelogenous leukemia cell-line with positive Philadephia-chromosome. Blood, 1975; 45: 321-334
81. Mansilla S., Priebe W., Portugal J.: Sp1-targeted inhibition of gene transcription by WP631 in transfected lymphocytes. Biochemistry, 2004; 43: 7584-7592
82. Marnett L.J.: Oxy radicals, lipid peroxidation and DNA damage. Txicology, 2002; 181-182: 219-222
83. Martin D., Salinas M., Fujita N., Tsuruo T., Cuadrado A.: Ceramide and reactive oxygen species generated by H2O2 induce caspase-3-independent degradation of Akt/protein kinase B. J. Biol. Chem., 2002; 277: 42943-42952
84. Martin F.J.: Clinical pharmacology and antitumor efficacy of DOXIL (pegylated liposomal doxorubicin), in Medical Applications of Liposomes. Elsevier Science Inc., New York 1998, 635-688
85. McBride N.C., Cavenagh J.D., Ward M.C., Grant I., Schey S., Gray A., Hughes A., Mills M.J., Cervi P., Newland A.C., Kelsey S.M.: Liposomal daunorubicin (DaunoXome) in combination with cyclophosphamide, vincristine and prednisolone (COP-X) as salvage therapy in poor-prognosis non-Hodgkins lymphoma. Leuk. Lymphoma, 2001; 42: 89-98
86. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L.: Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev., 2004; 56: 185-229
87. Minotti G., Ronchi R., Salvatorelli E., Menna P., Cairo G.: Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. Cancer Res., 2001; 61: 8422-8428
88. Moase E.H., Qi W., Ishida T., Gabos Z., Longenecker B.M., Zimmermann G.L., Ding L., Krantz M., Allen T.M.: Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer. Biochim. Biophys. Acta, 2001; 1510: 43-55
89. Mohrbacher A.F., Gregory S.A., Gabriel D.A., Rusk J.M., Giles F.J.: Liposomal daunorubicin (DaunoXome) plus dexamethasone for patients with multiple myeloma. A phase II International Oncology Study Group study. Cancer, 2002; 94: 2645-2652
90. Morceau F., Chenais B., Gillet R., Jardillier J.C., Jeannesson P., Trentesaux C.: Transcriptional and posttranscriptional regulation of erythroid gene expression in anthracycline-induced differentiation of human erythroleukemic cells. Cell Growth Differ., 1996; 7: 1023-1029
91. Mordente A., Minotti G., Martorana G.E., Silvestrini A., Giardina B., Meucci E.: Anthracycline secondary alcohol metabolite formation in human or rabbit heart: biochemical aspects and pharmacologic implications. Biochem. Pharmacol., 2003; 66: 989-998
92. Morin M.J., Sartorelli A.C.: Inhibition of glycoprotein biosynthesis by the inducers of HL-60 cell differentiation, aclacinomycin A and marcellomycin. Cancer Res., 1984; 44: 2807-2812
93. Muller C., Chatelut E., Gualano V., De Forni M., Huguet F., Attal M., Canal P., Laurent G.: Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion. Cancer Chemother. Pharmacol., 1993; 32: 379-384
94. Munger C., Ellis A., Woods K., Randolph J., Yanovich S., Gewirtz D.: Evidence for inhibition of growth related to compromised DNA synthesis in the interaction of daunorubicin with H-35 rat hepatoma. Cancer Res., 1988; 48: 2404-2411
95. Nabholtz J.M., Falkson C., Campos D., Szanto J., Martin M., Chan S., Pienkowski T., Zaluski J., Pinter T., Krzakowski M., Vorobiof D., Leonard R., Kennedy I., Azli N., Murawsky M., Riva A., Pouillart P.: TAX 306 Study Group. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J. Clin. Oncol., 2003; 21: 968-975
96. Nagy A., Armatis P., Schally A.V.: High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: structure-activity relationship of daunosamine-modified derivatives of doxorubicin. Proc. Natl. Acad. Sci. USA, 1996; 93: 2464-2469
97. Neri G. C., Bandinelli M., Neri B.: Free-radical production and nucleotide loss in anthracycline-induced cardiac damage. Med. Sci. Res., 1993; 21: 905-907
98. Niedernhofer L.J., Daniels J.S., Rouzer C.A., Greene R.E., Marnett L.J.: Malondialdehyde, a product of lipid peroxidation, is mutagenic in human cells. J. Biol. Chem., 2003; 278: 31426-31433
99. Nunez M., Saballs P., Valencia M.E., Santos J., Ferrer E., Santos I., Berrocal A., Galindo M.J., Podzamczer D., Gonzlez-Lahoz J.: Caelyx/KS Spanish Study Group. Response to liposomal doxorubicin and clinical outcome of HIV-1-infected patients with Kaposi's sarcoma receiving highly active antiretroviral therapy. HIV Clin. Trials, 2001; 2: 429-437
100. Nyoung M.N., Trentesaux C., Aries A., Carpentier Y., Jardillier J.C., Gorisse M.C., Jeannesson P.: Effect of aclacinomycin-doxorubicin association on differentiation and growth of human erythroleukemic K562 cells. Anticancer Res., 1994; 14: 1203-1208
101. Olinski R., Jaruga P., Foksinski M., Bialkowski K., Tujakowski J.: Epirubicin-induced oxidative DNA damage and evidence for its repair in lymphocytes of cancer patients who are undergoing chemotherapy. Mol. Pharmacol., 1997; 52: 882-885
102. Oliński R., Jurgowiak M.: Rola reaktywnych form tlenu w procesach mutagenezy i karcynogenezy. Post. Biochem., 1999; 45: 50-58
103. Olson R.D., Li X., Palade P., Shadle S.E., Mushlin P.S., Gambliel H.A., Fill M., Boucek R.J. Jr, Cusack B.J.: Sarcoplasmic reticulum calcium release is stimulated and inhibited by daunorubicin and daunorubicinol. Toxicol. Appl. Pharmacol., 2000; 169: 168-176
104. Pacher P., Liaudet L., Bai P., Mabley J.G., Kaminski P.M., Virag L., Deb A., Szabo E., Ungvari Z., Wolin M.S., Groves J.T., Szabo C.: Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation, 2003; 107: 896-904
105. Panaretakis T., Pokrovskaja K., Shoshan M.C., Grander D.: Activation of Bak, Bax, and BH3-only proteins in the apoptotic response to doxorubicin. J. Biol. Chem., 2002; 277: 44317-44326
106. Park J.W., Hong K., Kirpotin D.B., Colbern G., Shalaby R., Baselga J., Shao Y., Nielsen U.B., Marks J.D., Moore D., Papahadjopoulos D., Benz C.C.: Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin. Cancer Res., 2002; 8: 1172-1181
107. Pastorino F., Brignole C., Marimpietri D., Cilli M., Gambini C., Ribatti D., Longhi R., Allen T.M., Corti A., Ponzoni M.: Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res., 2003; 63: 7400-7409
108. Penault-Llorca F., Cayre A., Bouchet Mishellany F., Amat S., Feillel V., Le Bouedec G., Ferriere J.P., De Latour M., Chollet P.: Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. Int. J. Oncol., 2003; 22: 1319-1325
109. Perrin L.C., Cullinane C., Kimura K., Phillips D.R.: Barminomycin forms GC-specific adducts and virtual interstrand crosslinks with DNA. Nucleic Acids Res., 1999; 27: 1781-1787
110. Plastaras J.P., Dedon P.C., Marnett L.J.: Effects of DNA structure on oxopropenylation by the endogenous mutagens malondialdehyde and base propenal. Biochemistry, 2002; 41: 5033-5042
111. Portugal J., Martin B., Vaquero A., Ferrer N., Villamarin S., Priebe W.: Analysis of the effects of daunorubicin and WP631 on transcription. Curr. Med. Chem., 2001; 8: 1-8
112. Poulaki V., Mitsiades C.S., Joussen A.M., Lappas A., Kirchhof B., Mitsiades N.: Constitutive nuclear factor-kappaB activity is crucial for human retinoblastoma cell viability. Am. J. Pathol., 2002; 161: 2229-2240
113. Quigley G.J., Wang A.H., Ughetto G., van der Marel G., van Boom J.H., Rich A.: Molecular structure of an anticancer drug-DNA complex: daunomycin plus d(CpGpTpApCpG). Proc. Natl. Acad. Sci. USA, 1980; 77: 7204-7208
114. Reinert K.E.: Anthracycline-binding induced DNA stiffening, bending and elongation; stereochemical implications from viscometric investigations. Nucleic Acids Res., 1983; 11: 3411-3430
115. Ripamonti M., Capolongo L., Melegaro G., Gornati C., Bargiotti A., Caruso M., Grandi M., Suarato A.: Morpholinylanthracyclines: cytotoxicity and antitumor activity of differently modified derivatives. Invest. New Drugs, 1996; 14: 139-146
116. Rivera E., Valero V., Esteva F.J., Syrewicz L., Cristofanilli M., Rahman Z., Booser D.J., Hortobagyi G.N.: Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer. Cancer Chemother. Pharmacol., 2002; 49: 299-302
117. Robert J.: Epirubicin. Clinical pharmacology and dose-effect relationship. Drugs, 1993; 45(Suppl.2): 20-30
118. Robinson N.C.: Functional binding of cardiolipin to cytochrome c oxydase. J. Bioenerg. Biomembr.,1993; 25: 153-163
119. Rocchi P., Ferreri A.M., Simone G., Bagnara G.P., Paolucci G.: Neuronal cell differentiation of human neuroblastoma cells by inducing agents in combination. Anticancer Res., 1991; 11: 1885-1889
120. Rocchi P., Ferreri A.M., Simone G., Prodi G.: Epirubicin-induced differentiation of human neuroblastoma cells in vitro. Anticancer Res., 1987; 7: 247-250
121. Ruiz-Ruiz C., Robledo G., Cano E., Redondo J.M., Lopez-Rivas A.: Characterization of p53-mediated up-regulation of CD95 gene expression upon genotoxic treatment in human breast tumor cells. J. Biol. Chem., 2003; 278: 31667-31675
122. Schaefer A., Dahle M., Radenz G., Steinheider G., Marquardt H.: Structure-activity relationship between anthracycline-induced differentiation and inhibition of glycoprotein synthesis in Friend erythroleukemia cells. Leukemia, 1991; 5: 95-100
123. Schaefer A., Dressel A., Lingelbach K., Schmidt C.A., Steinheider G., Marquardt H.: Induction of differentiation in Friend-erythroleukemia cells by aclacinomycin A: early transient decrease in c-myc and c-myb mRNA levels. Leukemia, 1992; 6: 828-833
124. Schengrund C.L., Sheffler B.A.: Biochemical and morphological study of adriamycin-induced changes in murine neuroblastoma cells. Oncology, 1982; 39: 185-190
125. Schott B., Robert J.: Comparative cytotoxicity, DNA synthesis inhibition and drug incorporation of eight anthracyclines in a model of doxorubicin-sensitive and-resistant rat glioblastoma cells. Biochem. Pharmacol., 1989; 38: 167-172
126. Searle M.S., Hall J.G., Denny W.A., Wakelin L.P.: NMR studies of the interaction of the antibiotic nogalamycin with the hexadeoxyribonucleotide duplex d(5'-GCATGC)2. Biochemistry, 1988; 27: 4340-4349
127. Seymour L.W., Ferry D.R., Anderson D., Hesslewood S., Julyan P.J., Poyner R., Doran J., Young A.M., Burtles S., Kerr D.J., Cancer Research Campaign Phase I/II Clinical Trials Committee: Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J. Clin. Oncol., 2002; 20: 1668-1676
128. Sheikh M.S., Li X.S., Chen J.C., Shao Z.M., Ordonez J.V., Fontana J.A.: Mechanisms of regulation of WAF1/Cip1 gene expression in human breast carcinoma: role of p53-dependent and independent signal transduction pathways. Oncogene, 1994; 9: 3407-3415
129. Siegfried J.M., Sartorelli A.C., Tritton T.R.: Evidence for the lack of relationship between inhibition of nucleic acid synthesis and cytotoxicity of adriamycin. Cancer Biochem. Biophys., 1983; 6: 137-142
130. Singal P.K., Deally C.M., Weinberg L.E.: Subcellular effects of adriamycin in the heart: A concise review. J. Mol. Cell Cardiol., 1987; 19: 817-828
131. Singer B.: Fidelity in transcription assessed by DNA-dependent RNA polymerases. Biochimie, 1982; 64: 599-601
132. Smith C.K., Davies G.J., Dodson E.J., Moore M.H.: DNA-nogalamycin interactions: The crystal structure of d(TGATCA) complexed with nogalamycin. Biochemistry, 1995; 34: 415-425
133. Stahl M., Dijkers P.F., Kops G.J., Lens S.M., Coffer P.J., Burgering B.M., Medema R.H.: The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2. J. Immunol., 2002; 168: 5024-5031
134. Starzyński R.R., Lipiński P.: IRP1, białko kontrolujące homeostazę zelaza w komórkach ssaków: regulacja jego aktywnos̈ci przez jony zelaza i tlenek azotu. Post. Biol. Kom., 2003; 30: 497-514
135. Steinherz L.J., Steinherz P.G., Tan C.T., Heller G., Murphy M.L.: Cardiac toxicity 4 to 20 years after completing anthracycline therapy. J.A.M.A., 1991; 266: 1672-1677
136. Stocker U., Schaefer A., Marquardt H.: DMSO-like rapid decrease in c-myc and c-myb mRNA levels and induction of differentiation in HL-60 cells by the anthracycline antitumor antibiotic aclarubicin. Leukemia, 1995; 9: 146-154
137. Storm G., Steerenberg P.A., Emmen F., van Borssum Waalkes M., Crommelin D.J.: Release of doxorubicin from peritoneal macrophages exposed in vivo to doxorubicin-containing liposomes. Biochim. Biophys. Acta, 1988; 965: 136-145
138. Studzian K., Wasowska M., Piestrzeniewicz M.K., Wilmanska D., Szmigiero L., Oszczapowicz I., Gniazdowski M.: Inhibition of RNA synthesis in vitro and cell growth by anthracycline antibiotics. Neoplasma, 2001; 48: 412-418
139. Suh D., Oh Y.K., Hur M.W., Ahn B., Chaires J.B.: Daunomycin binding to deoxypolynucleotides with alternating sequences: complete thermodynamic profiles of heterogeneous binding sites. Nucleosides Nucleotides Nucleic Acids, 2002; 21: 637-649
140. Supino R., Mariani M., Colombo A., Prosperi E., Croce A.C., Bottiroli G.: Comparative studies on the effects of doxorubicin and differentiation inducing agents on B16 melanoma cells. Eur. J. Cancer, 1992; 28A: 778-783
141. Szulawska A., Gniazdowski M., Czyz M.: Sequence specificity of formaldehyde-mediated covalent binding of anthracycline derivatives to DNA. Biochem. Pharmacol., 2005; 69: 7-18
142. Taatjes D.J., Fenick D.J., Koch T.H.: Nuclear targeting and nuclear retention of anthracycline-formaldehyde conjugates implicates DNA covalent bonding in the cytotoxic mechanism of anthracyclines. Chem. Res. Toxicol., 1999; 12: 588-596
143. Taatjes D.J., Gaudiano G., Koch T.H.: Production of formaldehyde and DNA-adriamycin or DNA-daunomycin adducts, initiated through redox chemistry of dithiothreitol/iron, xanthine oxidase/NADH/iron, or glutathione/iron. Chem. Res. Toxicol., 1997; 10: 953-961
144. Taatjes D.J., Gaudiano G., Resing K., Koch T.H.: Alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin. J. Med. Chem., 1996; 39: 4135-4138
145. Taatjes D.J., Gaudiano G., Resing K., Koch T.H.: Redox pathway leading to the alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin. J. Med. Chem., 1997; 40: 1276-1286
146. Taatjes D.J., Koch T.H.: Nuclear targeting and retention of anthracycline antitumor drugs in sensitive and resistant tumor cells. Curr. Med. Chem., 2001; 8: 15-29
147. Tanaka M., Yoshida S.: Mechanism of the inhibition of calf thymus DNA polymerases alpha and beta by daunomycin and adriamycin. J. Biochem., 1980; 87: 911-918
148. Testa U., Pelosi E., Peschle C.: The transferrin receptor. Cit. Rev. Oncog., 1993; 4: 241-276
149. Thomas A.L., O'Byrne K., Furber L., Jeffery K., Steward W.P.: A phase II study of caelyx, liposomal doxorubicin: lack of activity in patients with advanced gastric cancer. Cancer Chemother. Pharmacol., 2001; 48: 266-268
150. Toffoli G., Viel A., Bevilacqua C., Maestro R., Tumiotto L., Boiocchi M.: In K562 leukemia cells treated with doxorubicin and hemin, a decreas In c-myc mRNA expression correlates with los sof self-renewal capability but not with erythroid differentiation. Leuk. Res., 1989; 13: 279-287
151. Tokarska-Schlattner M., Wallimann T., Schlattner U.: Multiple interference of anthracyclines with mitochondrial creatine kinases: preferential damage of the cardiac isoenzyme and its implications for drug cardiotoxicity. Mol. Pharmacol., 2002; 61: 516-523
152. Tonini G.P., Radzioch A., Gronberg A., Clayton M., Blasi E., Benetton G., Varesio L.: Erythroid differentiation and modulation of c-myc expression induced by antineoplastic drugs in the human leukemic cell line K562. Cancer Res., 1987; 47: 4544-4547
153. Trentesaux C., Nyoung M.N, Aries A., Morceau F., Ronchi A., Ottolenghi S., Jardillier J.C., Jeannesson P.: Increased expression of GATA-1 and NFE-2 erythroid-specific transcription factor during aclacynomycin-mediated differentiation of human erythroleukemic cells. Leukemia, 1993; 7: 452-457
154. Trouet A., Passioukov A., Van derpoorten K., Fernandez A.M., Abarca-Quinones J., Baurain R., Lobl T.J., Oliyai C., Shochat D., Dubois V.: Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer: application to doxorubicin and preliminary in vitro and in vivo studies. Cancer Res., 2001; 61: 2843-2846
155. Tuteja N., Phan T.N., Tuteja R., Ochem A., Falaschi A.: Inhibition of DNA unwinding and ATPase activities of human DNA helicase II by chemotherapeutic agents. Biochem. Biophys. Res. Commun., 1997; 236: 636-640
156. van Rosmalen A., Cullinane C., Cutts S.M., Phillips D.R.: Stability of adriamycin-induced DNA adducts and interstrand crosslinks. Nucleic Acids Res., 1995; 23: 42-50
157. Vasquez-Vivar J., Martasek P., Hogg N., Masters B.S., Pritchard K.A. Jr, Kalyanaraman B.: Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry, 1997; 36: 11293-11297
158. Wang S., Kotamraju S., Konorev E., Kalivendi S., Joseph J., Kalyanaraman B.: Activation of nuclear factor-kappaB during doxorubicin-induced apoptosis in endothelial cells and myocytes is proapoptotic: The role of hydrogen peroxide. Biochem. J., 2002; 367: 729-740
159. Weiss R.B.: The anthracyclines: will we ever find a better doxorubicin? Semin. Oncol., 1992; 19: 670-686
160. White R.J, Phillips D.R.: Sequence-dependent termination of bacteriophage T7 transcription in vitro by DNA-binding drugs. Biochemistry, 1989; 28: 4277-4283
161. Williams L.D., Egli M., Qi G., Bash P., van der Marel G.A., van Boom J.H., Rich A., Frederick C.A.: Structure of nogalamycin bound to a DNA hexamer. Proc. Natl. Acad. Sci. USA., 1990; 87: 2225-2229
162. Yamaoka M., Yamaguchi S., Suzuki T., Okuyama M., Nitobe J., Nakamura N., Mitsui Y., Tomoike H.: Apoptosis in rat cardiac myocytes induced by Fas ligand: priming for Fas-mediated apoptosis with doxorubicin. J. Mol. Cell Cardiol., 2000; 32: 881-889
163. Zastawny T.H.: Oksydacyjne uszkodzenia DNA-wolnorodnikowe modyfikacje zasad i deoksyrybozy. Post. Biochem., 1997; 43: 238-250
164. Zeman S.M., Phillips D.R., Crothers D.M.: Characterization of covalent adriamycin-DNA adducts. Proc. Natl. Acad. Sci. USA, 1998; 95: 11561-11565
165. Zha J., Harada H., Yang E., Jockel J., Korsmeyer S.J.: Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell, 1996; 87: 619-628
166. Zucchi R., Danesi R.: Cardiac toxicity of antineoplastic anthracyclines. Curr. Med. Chem. Anticancer Agents, 2003; 3: 151-171
167. Zwelling L.A., Altschuler E., Cherif A., Farquhar D.: N-(5,5-diacet oxypentyl)doxorubicin: A novel anthracycline producing DNA interstrand cross-linking and rapid endonucleolytic cleavage in human leukemia cells. Cancer Res., 1991; 51: 6704-6707